(Total Views: 564)
Posted On: 02/10/2025 9:15:00 AM
Post# of 155808
Re: chazzledazzle #150028
ChatGpt said
If NIH grants, including previously awarded ones, are being cut and the RECOVER initiative is shut down, CytoDyn (CYDY) could face some indirect effects, but the impact would likely be minimal overall.
Potential Impacts:
Long COVID Study:
If RECOVER shuts down, CytoDyn won’t receive NIH funding or support for leronlimab in Long COVID trials.
However, the company has already planned for this possibility by shifting focus to ME/CFS trials, meaning the research direction would continue—just independently.
ME/CFS Study Continuation:
Since the ME/CFS study was paused in favor of the Long COVID opportunity, it can be restarted if NIH funding disappears.
While independent studies require more internal funding or alternative sources, CytoDyn appears to have a contingency plan in place.
Minimal Financial Impact:
CytoDyn historically operates through private funding, stock offerings, and partnerships rather than relying heavily on NIH grants.
The NIH decision mainly affects the timeline of their studies, not necessarily their ability to conduct research altogether.
Bottom Line:
While the NIH cuts might slow progress or shift strategic priorities, CytoDyn’s adaptability—by pivoting to ME/CFS—suggests the overall impact would be limited rather than critical.
If NIH grants, including previously awarded ones, are being cut and the RECOVER initiative is shut down, CytoDyn (CYDY) could face some indirect effects, but the impact would likely be minimal overall.
Potential Impacts:
Long COVID Study:
If RECOVER shuts down, CytoDyn won’t receive NIH funding or support for leronlimab in Long COVID trials.
However, the company has already planned for this possibility by shifting focus to ME/CFS trials, meaning the research direction would continue—just independently.
ME/CFS Study Continuation:
Since the ME/CFS study was paused in favor of the Long COVID opportunity, it can be restarted if NIH funding disappears.
While independent studies require more internal funding or alternative sources, CytoDyn appears to have a contingency plan in place.
Minimal Financial Impact:
CytoDyn historically operates through private funding, stock offerings, and partnerships rather than relying heavily on NIH grants.
The NIH decision mainly affects the timeline of their studies, not necessarily their ability to conduct research altogether.
Bottom Line:
While the NIH cuts might slow progress or shift strategic priorities, CytoDyn’s adaptability—by pivoting to ME/CFS—suggests the overall impact would be limited rather than critical.
(5)
(0)
